Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood-Based injection shows promise for slowing dry AMD

NCT ID NCT07428798

Disease control Sponsor: Marmara University Pendik Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting a concentrated form of a patient's own blood, called platelet-rich plasma (PRP), into the eye could slow the progression of advanced dry age-related macular degeneration (AMD). Fourteen people with advanced dry AMD received three PRP injections in one eye, while the other eye was left untreated as a comparison. The goal was to see if the treatment could reduce the growth of damaged areas in the retina and help preserve vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Jul 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 60 years 2. Diagnosis of advanced dry age-related macular degeneration (AMD) in both eyes 3. No previous ocular treatment for AMD 4. History of ocular surgery limited to cataract surgery performed ≥1 year prior Exclusion Criteria: 1. Media opacities interfering with retinal imaging assessment 2. Any ocular disease other than dry AMD that could affect retinal structure or function 3. Evidence of macular neovascularization 4. Previous intraocular surgery other than cataract surgery 5. Systemic or ocular conditions that could affect study compliance or visual testing reliability

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry age-related macular degeneration Geographic atrophy

Contacts and locations

Locations

  • Marmara University School of Medicine, Department of Ophthalmology

    Istanbul, Istanbul, 34899, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.